Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Theracion Biomedical Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, WORSHAM, JESSICA N, and 1 distinct art unit. WORSHAM, JESSICA N is the busiest examiner with 1 pending action, representing the company's total active prosecution. This biotech case is the sole matter currently requiring office interaction, which allows the company to focus its resources on a single set of technical claims.
Because the company is managing only 1 pending office action, it can focus its resources on the specific technical challenges presented by the 1 distinct art unit. The outcome of this biotechnology matter depends entirely on the interpretation of WORSHAM, JESSICA N, who is the 1 distinct examiner assigned to the case. Practitioners should prioritize a thorough review of this examiner's previous actions to ensure that the response to the 1 pending office action is tailored to her specific procedural and technical preferences. This focused approach can lead to a more efficient path toward allowance for the company's biomedical innovations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WORSHAM, JESSICA N | 1 | 56.6% | +56.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801937 | MULTI-USE HEMOSTATIC COMPOSITION AND METHOD FOR PRODUCING SAME | WORSHAM, JESSICA N | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17801937 | MULTI-USE HEMOSTATIC COMPOSITION AND METHOD FOR PRODUCING SAME | WORSHAM, JESSICA N | 1615 | §103 | Final Rejection | — | Pending | Jan 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTheracion Biomedical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jessica N Worsham has the most, with 1 of Theracion Biomedical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
